Kisqali (600 MG Dose) and Roflumilast
Determining the interaction of Kisqali (600 MG Dose) and Roflumilast and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using roflumilast together with ribociclib may have additive effects on the immune system, possibly increasing the risk of infections or immunologic disorders. You may not be able to use roflumilast if you have a serious infection, cancer, or an immune-based disorder such as HIV infection, multiple sclerosis, or lupus. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor and a nonsteroidal anti-inflammatory agent. In experimental models and in vitro studies, roflumilast has exhibited immunomodulatory effects. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.
MANAGEMENT: According to the product labeling for roflumilast in some countries such as Canada and the U.K., concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Daxas (roflumilast)." Nycomed Inc, Princeton, NJ.
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Kisqali (600 MG Dose)-Roflumilast Tablets
- Kisqali (600 MG Dose)-Rogaine
- Kisqali (600 MG Dose)-Rogaine (Minoxidil Topical Foam)
- Kisqali (600 MG Dose)-Rogaine (Minoxidil Topical Solution)
- Kisqali (600 MG Dose)-Rogaine Extra Strength Mens
- Kisqali (600 MG Dose)-Rogaine For Men Extra Strength Topical
- Roflumilast-Kisqali Femara Co-Pack
- Roflumilast-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Roflumilast-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Roflumilast-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Roflumilast-Kitabis Pak
- Roflumilast-Kitabis Pak inhalation